These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18566028)

  • 1. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
    Minden S; Hoaglin D; Jureidini S; Hadden L; Frankel D; Komatsuzaki Y; Outley J
    Mult Scler; 2008 Jun; 14(5):640-55. PubMed ID: 18566028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
    Lonergan R; Kinsella K; Duggan M; Jordan S; Hutchinson M; Tubridy N
    Mult Scler; 2009 Dec; 15(12):1528-31. PubMed ID: 19995848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease progression in multiple sclerosis: combining physicians' and patients' perspectives?
    Kragt JJ; Nielsen JM; van der Linden FA; Polman CH; Uitdehaag BM
    Mult Scler; 2011 Feb; 17(2):234-40. PubMed ID: 20978037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.
    Hawton A; Green C; Telford CJ; Wright DE; Zajicek JP
    Mult Scler; 2012 Jun; 18(6):853-61. PubMed ID: 22108867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow up of glatiramer acetate compassionate use in Belgium.
    Sindic CJ; Seeldrayers P; Vande Gaer L; De Smet E; Nagels G; De Deyn PP; Medaer R; Guillaume D; D'Hooghe MB; Deville MC; Decoo D; Sadzot B; Van Landegem W; Strauven T; Pepin J; Merckx H; Caekebeke J; van der Tool MA
    Acta Neurol Belg; 2005 Jun; 105(2):81-5. PubMed ID: 16076061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study.
    Wu N; Minden SL; Hoaglin DC; Hadden L; Frankel D
    J Health Hum Serv Adm; 2007; 30(3):233-67. PubMed ID: 18236703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
    Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis.
    Gold SM; Raji A; Huitinga I; Wiedemann K; Schulz KH; Heesen C
    J Neuroimmunol; 2005 Aug; 165(1-2):186-91. PubMed ID: 15935481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with the risk of secondary progression in multiple sclerosis.
    Koch M; Uyttenboogaart M; van Harten A; De Keyser J
    Mult Scler; 2008 Jul; 14(6):799-803. PubMed ID: 18573840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender change and its impact on the course of multiple sclerosis.
    Reske D; Haupt WF; Petereit HF
    Acta Neurol Scand; 2006 May; 113(5):347-9. PubMed ID: 16629772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
    Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.
    Vercellino M; Romagnolo A; Mattioda A; Masera S; Piacentino C; Merola A; Chiò A; Mutani R; Cavalla P
    Acta Neurol Scand; 2009 Feb; 119(2):126-30. PubMed ID: 18684216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multiple sclerosis. Therapeutic nihilism is the wrong approach here].
    Voltz R; Goebels N; Jarius S; Hohlfeld R
    MMW Fortschr Med; 2002 May; Suppl 2():52-7. PubMed ID: 12070851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis.
    Visser LH; van der Zande A
    Eur J Neurol; 2011 Nov; 18(11):1343-9. PubMed ID: 21496180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.